Ben Maldonato

Ben Maldonato is a Senior Scientist I at Revolution Medicines since January 2022, where responsibilities include serving as a DMPK functional representative on discovery and development phase projects. Previously, Ben worked as a Scientist at Rigel Pharmaceuticals Inc., focusing on bioanalytical and non-clinical ADME/PK projects. Academic qualifications include a PhD in Medicinal and Pharmaceutical Chemistry from the University of Washington, where thesis work involved characterizing a novel methyltransferase, METTL7B. Additional experience includes a summer internship in DMPK at Boehringer Ingelheim and research roles at the University of Virginia and the University of Washington, aimed at enzymatic activity and method development in drug metabolism.